Pharmacokinetics in stable heart transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations

Journal of Heart and Lung Transplantation

Volumn 30, Issue 9, 2011, Pages 1003-1010

  Alloway, Rita ^a   Vanhaecke, Johan ^b   Yonan, Nizar ^c   White, Michel ^d   Haddad, Haissam ^e   Rábago, Gregorio ^f   Tymchak, Wayne ^g   Molina, Beatriz Diaz ^h   Grimm, Michael ⁱ   Eiskjaer, Hans ^j   Karpf, Carmen ^k   Undre, Nasrullah ^l  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c WYTHENSHAWE HOSPITAL   (United Kingdom)

^d MONTREAL HEART INSTITUTE   (Canada)

^e UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^f UNIVERSITY CLINIC OF NAVARRA   (Spain)

^g UNIVERSITY OF ALBERTA   (Canada)

^h HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^j AARHUS UNIVERSITY HOSPITAL   (Denmark)

^k Astellas GmbH   (Germany)

^l ASTELLAS PHARMA EUROPE LTD   (United Kingdom)

more..

Author keywords

heart transplantation; once daily tacrolimus; pharmacokinetics; prolonged release tacrolimus; tacrolimus

Indexed keywords

TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CARDIAC GRAFT REJECTION; CONTROLLED STUDY; DEATH; DOSAGE SCHEDULE COMPARISON; DRUG FORMULATION; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GRAFT FAILURE; GRAFT RECIPIENT; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE OBSTRUCTION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OPEN STUDY; PHARMACOLOGICAL PARAMETERS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; UROGENITAL TRACT DISEASE;

ADULT; AGED; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TACROLIMUS; TRANSPLANTATION;

EID: 80051469540     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2011.02.008     Document Type: Article

References (18)

1. D.O. Taylor, M.L. Barr, and B. Radovancevic A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus J Heart Lung Transplant 18 1999 336 345 (Pubitemid 29205269)
2. M. Grimm, M. Rinaldi, and N.A. Yonan Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipientsa large European trial Am J Transplant 6 2006 1387 1397 (Pubitemid 44030321)
3. L.J. Scott, K. McKeage, S.J. Keam, and G.L. Plosker Tacrolimus: a further update of its use in the management of organ transplantation Drugs 63 2003 1247 1297 (Pubitemid 36750952)
4. R. Alloway, S. Steinberg, and K. Khalil Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen Transplant Proc 37 2005 867 870 (Pubitemid 40590728)
5. S. Florman, R. Alloway, and M. Kalayoglu Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen Transplant Proc 37 2005 1211 1213 (Pubitemid 40590839)
6. A.M. Alak, S. Moy, and M. Cook An HPLC/MS/MS assay for tacrolimus in patient blood samples Correlation with results of an ELISA assay J Pharm Biomed Anal 16 1997 7 13 (Pubitemid 27462682)
7. M.E. Billingham, N.R. Cary, and M.E. Hammond A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group The International Society for Heart Transplantation J Heart Transplant 9 1990 587 593
8. M. First, and W. Fitzsimmons New drugs to improve transplant outcomes Transplantation 77 2004 S88 S92
9. B.M. Meiser, M. Pfeiffer, and D. Schmidt Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring J Heart Lung Transplant 18 1999 143 149 (Pubitemid 29159294)
10. D.A. Baran, L. Segura, and S. Kushwaha Tacrolimus monotherapy in adult cardiac transplant recipients: intermediate-term results J Heart Lung Transplant 20 2001 59 70 (Pubitemid 32112386)
11. S.M. Pham, R.L. Kormos, and B.G. Hattler A prospective trial of tacrolimus (FK 506) in clinical heart transplantation: intermediate-term results J Thorac Cardiovasc Surg 111 1996 764 772 (Pubitemid 26119678)
12. Z. Wlodarczyk, J.-P. Squifflet, and M. Ostrowski Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial Am J Transplant 9 2009 2505 2513
13. L. Fischer, P. Truneka, and B. Gridelli Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo liver transplantation: a randomized, open-label trial Liver Transplant 17 2011 167 177
14. J.P. van Hooff, R.R. Alloway, P. Truneka, and M. Mourad Four-year experience with tacrolimus once-daily prolonged release in patients from phase II conversion and de novo kidney, liver, and heart studies Clin Transplant 25 2011 E1 E12
15. S. Pondrom Can generics be trusted? Am J Transplant 10 2010 708 709
16. R.R. Alloway, R. Isaacs, and K. Lake Report of the American Society of Transplantation Conference on immunosuppressive drugs and the use of generic immunosuppressants Am J Transplant 3 2003 1211 1215 (Pubitemid 37214617)
17. P.A. Uber, H.J. Ross, and A.O. Zuckermann Generic drug immunosuppression in thoracic transplantation: an ISHLT educational advisory J Heart Lung Transplant 28 2009 655 660
18. U. Christians, J. Klawitter, and C.F. Clavijo Bioequivalence testing of immunosuppressants: concepts and misconceptions Kidney Int Suppl 77 2010 S1 S7